Welcome to the Digital 5th Liquid Biopsy for Precision Oncology Summit!

With two exciting LBx approvals in 2020 and investment pouring into the industry, these assays are primed to transform the cancer-care space. To realize these untapped opportunities, it is essential significant sensitivity, selectivity and analytical roadblocks are addressed to prove utility in the clinic.

The 5th Annual Liquid Biopsy for Precision Oncology Summit is a crucial date in the industry calendar, bringing together the entire value chain of oncology drug development to hear and collaborate around the latest advancements innovating cancer detection, diagnosis and monitoring.

This completely online meeting will allow you to discover how latest technologies are being applied to accurately detect and analyze circulating biomarkers earlier, effectively monitor treatment response and selectively stratify patient populations to enable delivery of targeted therapies in a time-efficient manner.

From biomarker validation through to reimbursement and regulatory, join your drug development peers striving to translate the clinical applications of liquid biopsies into a worldwide patient reality.

To know more about 5th Annual Liquid Biopsies for Precision Oncology Summit please click here.